TCRX - NASDAQ
TScan Therapeutics, Inc.
$1.01
+4.6%TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
At a Glance
Live Snapshottcrx
Additional Paid-In Capital
Last Annual Value
627.98M
3-Year CAGR
35%
5-Year CAGR
258%
10-Year CAGR
117%
TScan Therapeutics, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
TScan Therapeutics, Inc. NASDAQ:TCRX | 627.98M | 16.4% | 19.9% | N/A | |
 Fortress Biotech, Inc. NASDAQ:FBIO | 783.89M | 3.0% | 3.6% | 10.7% | |
 Adicet Bio, Inc. NASDAQ:ACET | 773.79M | 12.0% | 10.4% | N/A | |
 XBiotech Inc. NASDAQ:XBIT | 0.00 | N/A | N/A | N/A | |
 Context Therapeutics Inc. NASDAQ:CNTX | 191.29M | 33.8% | 19.8% | N/A | |
 TuHURA Biosciences, Inc. NASDAQ:HURA | 161.78M | 23.0% | 27.1% | 16.0% | |
 Surrozen, Inc. NASDAQ:SRZN | 339.52M | 9.4% | 6.1% | N/A | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 481.96M | 12.0% | 8.8% | 13.8% | |
 Agenus Inc. NASDAQ:AGEN | 1.91B | 2.2% | 4.7% | 8.2% | |
 Inovio Pharmaceuticals, Inc. NASDAQ:INO | 1.84B | 1.9% | 2.7% | 12.7% | |
 Nautilus Biotechnology, Inc. NASDAQ:NAUT | 0.00 | N/A | N/A | N/A |
TScan Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your TCRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.